These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 7621237

  • 1. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness.
    Zier KS, Salvadori S, Cronin KC, Gansbacher B.
    Cancer Gene Ther; 1994 Mar; 1(1):43-50. PubMed ID: 7621237
    [Abstract] [Full Text] [Related]

  • 2. Functional defects are associated with abnormal signal transduction in T cells of mice inoculated with parental but not IL-2 secreting tumor cells.
    Salvadori S, Gansbacher B, Zier K.
    Cancer Gene Ther; 1994 Sep; 1(3):165-70. PubMed ID: 7542552
    [Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.
    J Immunol; 1998 Dec 15; 161(12):6977-84. PubMed ID: 9862733
    [Abstract] [Full Text] [Related]

  • 4. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors.
    Salvadori S, Gansbacher B, Pizzimenti AM, Zier KS.
    J Immunol; 1994 Dec 01; 153(11):5176-82. PubMed ID: 7963575
    [Abstract] [Full Text] [Related]

  • 5. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E.
    J Immunol; 1994 Mar 01; 152(5):2324-32. PubMed ID: 7907636
    [Abstract] [Full Text] [Related]

  • 6. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T, Chang AE, Shu SY.
    J Immunol; 1988 Apr 01; 140(7):2453-61. PubMed ID: 2450925
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
    Sun T, Kim TS, Waltz MR, Cohen EP.
    Cancer Gene Ther; 1995 Sep 01; 2(3):183-90. PubMed ID: 8528961
    [Abstract] [Full Text] [Related]

  • 8. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.
    McBride WH, Thacker JD, Comora S, Economou JS, Kelley D, Hogge D, Dubinett SM, Dougherty GJ.
    Cancer Res; 1992 Jul 15; 52(14):3931-7. PubMed ID: 1617669
    [Abstract] [Full Text] [Related]

  • 9. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.
    Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E.
    Cancer Res; 1990 Dec 15; 50(24):7820-5. PubMed ID: 2123742
    [Abstract] [Full Text] [Related]

  • 10. Immune response to somatic cell hybrids between ultraviolet radiation-induced regressor and spontaneous progressor C3H mouse tumor cells.
    Chen PW, Kaba DS, Ananthaswamy HN.
    Cancer Res; 1990 Mar 01; 50(5):1544-9. PubMed ID: 2137370
    [Abstract] [Full Text] [Related]

  • 11. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
    Grohmann U, Silla S, Belladonna ML, Bianchi R, Orabona C, Puccetti P, Fioretti MC.
    Cell Immunol; 1997 Nov 01; 181(2):109-19. PubMed ID: 9398398
    [Abstract] [Full Text] [Related]

  • 12. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
    Pippin BA, Rosenstein M, Jacob WF, Chiang Y, Lotze MT.
    Cancer Gene Ther; 1994 Mar 01; 1(1):35-42. PubMed ID: 7621236
    [Abstract] [Full Text] [Related]

  • 13. IL-2 gene transfer in immunotherapy of cancer: local administration of IL-2-activated lymphocytes and X63-m-IL-2 cells constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice.
    Bubeník J, Lotzová E, Indrová M, Simová J, Jandlová T, Savary CA.
    Nat Immun Cell Growth Regul; 1991 Mar 01; 10(5):247-55. PubMed ID: 1758466
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M, Hara I, Furukawa J, Oniki S, Nagai H, Miyake H, Fujisawa M.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
    Naito K, Nomi S, Komichi H, Ueda Y, Yamagishi H, Oka T, Pellis NR, Kahan BD.
    Cancer Detect Prev; 1992 Oct 01; 16(5-6):321-7. PubMed ID: 1361881
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.